BioSpace News Archive

Medicure Inc. through its pharmacy subsidiary Marley Drug®, a trusted national pharmacy known for its commitment to affordable healthcare solutions, is pleased to announce a partnership with TheracosBio to distribute a newly approved diabetes drug, BRENZAVVY® tablets, a sodium-glucose cotransporter-2 inhibitor, at an affordable cash price delivered directly to patient homes in all 50 US states and territories.

Kazia Therapeutics Limited announced the closing of its previously announced purchase and sale of up to an aggregate of 4,444,445 of the Company’s American Depositary Shares, each ADS representing ten ordinary shares of the Company, at a purchase price of $0.45 per ADS, in a registered direct offering.

Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.

Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1.

SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of the HER2-specific HIRE platform ADC, BL-M07D1, in the Investigational New Drug (IND) application on November 28, 2023.

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share.

J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI ‘JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.

EsoCap AG announced that the ACESO Phase II study comparing ESO-101 to placebo for the treatment of eosinophilic esophagitis has met its primary endpoint by significantly reducing the peak eosinophil count in the histological assessment of esophageal biopsies.

CorWave, a French company that develops and manufactures innovative cardiac assist devices, announces the appointment of Fairuz Hasni as Vice President Human Resources.

Ascletis Pharma Inc. announces initiation of the Phase III clinical trial of fatty acid synthase inhibitor ASC40 for treatment of moderate to severe acne vulgaris.